Skip to main content

Table 3 Number (n/tot) and percentage (%) of dogs infected with Capillaria aerophila and/or Capillaria boehmi showing one or more clinical signs related to upper/lower respiratory tract on Day 0, Day 28 and Day 56

From: Efficacy of milbemycin oxime/afoxolaner chewable tablets (NEXGARD SPECTRA®) against Capillaria aerophila and Capillaria boehmi in naturally infected dogs

Clinical sign

Group

Day 0

Day 28

Day 56

Sneezing

1

1/25

1/25

1/25

2

3/26

0/26

0/26

Reverse sneezing

1

1/25

1/25

1/25

2

0/26

1/26

0/26

Nasal discharge

1

0/25

0/25

0/25

2

4/26

3/26

0/26

Bronchovesicular sounds

1

0/25

0/25

2/25

2

3/26

0/26

0/26

Chronic dry cough

1

4/25

4/25

4/25

2

7/26

2/26

1/26

Dry cough

1

0/25

0/25

1/26

2

0/26

0/26

0/26

Number of dogs with at least one clinical sign

1

6/25 (24%)

6/25 (24%)

8/25 (32%)

2

13/26 (50.0%)

6/26 (23.1%)

1/26 (3.8%)

  1. Group 1: dogs treated with the negative control product NEXGARD®
  2. Group 2: dogs treated with NEXGARD SPECTRA®